MétaCan
Menu
← Back to cohort
Record W2301146256 · doi:10.1016/s0140-6736(15)01235-0

Defining new standards of care for men with prostate cancer

2016· letter· en· W2301146256 on OpenAlexaboutno aff
Howard I. Scher

Bibliographic record

VenueThe Lancet · 2016
Typeletter
Languageen
FieldMedicine
TopicProstate Cancer Treatment and Research
Canadian institutionsnot available
Fundersnot available
KeywordsProstate cancerMedicineDocetaxelAndrogen deprivation therapyOncologyHormonal therapyRandomized controlled trialInternal medicineCancerHormone therapyTestosterone (patch)GynecologyProstate-specific antigenBreast cancer

Abstract

fetched live from OpenAlex

Improving the outcomes of medical or surgical castration for men with prostate cancer has been an elusive goal since the approach was first reported in the 1940s.1 However, this situation changed at the annual American Society of Clinical Oncology meeting in 2014, when results reported from the ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease (CHAARTED) showed that addition of six cycles of docetaxel to standard of care (testosterone lowering hormone therapy) prolonged the survival of men with metastatic disease at the time of diagnosis relative to treatment with hormones alone.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.102
metaresearch head score (Gemma)0.204
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesnone
DomainCandidate signal: Methods · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Commentary · Consensus signal: Commentary
Teacher disagreement score0.898
Threshold uncertainty score0.538

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.1020.204
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0020.003
Bibliometrics0.0040.003
Science and technology studies0.0050.012
Scholarly communication0.0140.016
Open science0.0090.023
Research integrity0.0140.034
Insufficient payload (model declined to judge)0.0090.003

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.032
GPT teacher head0.354
Teacher spread0.322 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

Study designNot applicable
DomainMethods
GenreCommentary

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2016
Admission routes1
Has abstractyes

Explore more

Same venueThe Lancet→Same topicProstate Cancer Treatment and Research→French-language works237,207→